Covista Beats FY2026 Guidance, Revenue Hits $1.95B; Initiates FY2027 Outlook
CVSA sits 44% above its 52-week low of $86.97.
Summary
Covista reported fiscal year 2026 results that exceeded its own financial guidance, with revenue climbing 9.3% to $1.95 billion and adjusted EPS of $8.25. The company also initiated fiscal year 2027 guidance, signaling confidence in continued growth. Operating income expanded to $383.4 million, and adjusted EBITDA margin improved to 26.7%. The results were accompanied by several strategic announcements: a nursing collaboration with Advocate Health, two new Chamberlain University campuses, and expanded AI certificate offerings with Google Cloud. This follows a series of routine insider sales under 10b5-1 plans in July, which do not detract from the strong operational performance. The beat and new guidance provide a fresh catalyst for the stock, as the market digests the magnitude of the outperformance and the forward outlook.
At the time of this announcement, CVSA was trading at $125.32 on NYSE in the Trade & Services sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $86.97 to $156.26. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.